Acceleron Pharma, Inc.

Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma

Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma

April 3, 2012

-- Enhanced Anti-Tumor Activity Achieved via Combination of Two Distinct Anti-Angiogenic Drugs presented at the AACR Annual Meeting 2012 --

BIND Therapeutics, Inc.

Bind Biosciences - Fierce's 5 Drug Delivery Companies to Watch

Bind Biosciences - Fierce's 5 Drug Delivery Companies to Watch

March 27, 2012

Company: Bind Biosciences
Headquarters: Cambridge, MA
Founded: 2006
Employees: 30

Core drug delivery technology: Bind's Accurins technology blends polymers with existing drugs to create an enhanced, controlled-release compound that hits a precise target with its payload. Bind's first drug, Bind-014, is a formulation of docetaxel, the active ingredient in Taxotere, a drug that treats breast, prostate, lung and other cancers.

Tetraphase Pharmaceuticals, Inc.

Tetraphase Presents Data at ECCMID from Growing Portfolio of Next-Generation Antibiotic Candidates

Tetraphase Presents Data at ECCMID from Growing Portfolio of Next-Generation Antibiotic Candidates

April 2, 2012
- Data Highlight Enhanced Potency and Favorable Pharmacokinetics of New Agents Against Pseudomonas and Gram-Negative Respiratory Pathogens -
Avedro, Inc.

ACOS and Avedro Announce Initiation of a Phase 3 Study On Accelerated Corneal Cross-Linking

ACOS and Avedro Announce Initiation of a Phase 3 Study On Accelerated Corneal Cross-Linking

April 3, 2012

ACOS (The American-European Congress of Ophthalmic Surgery) and Avedro, Inc. jointly announced today the initiation of a Phase 3, multi-center, randomized, controlled evaluation to study accelerated corneal collagen cross-linking in eyes with keratoconus or corneal ectasia after refractive surgery. ACOS is sponsoring the study, which will be conducted in 100 clinical centers across the United States.

Mascoma and Lallemand Ethanol Technology Announce Commercial Agreement with Pacific Ethanol for Drop-In MGT™ Yeast Product and Commercial Roll-Out Progress

Mascoma and Lallemand Ethanol Technology Announce Commercial Agreement with Pacific Ethanol for Drop-In MGT™ Yeast Product and Commercial Roll-Out Progress

March 29, 2012

Mascoma Corporation, a renewable fuels company, and Lallemand Ethanol Technology, a leading supplier of fermentation ingredients to fuel ethanol producers, announced today that they have entered into a commercial agreement with Pacific Ethanol Columbia, LLC, the owner of the ethanol production facility located in Boardman, Oregon and operated by Pacific Ethanol, Inc., (NASDAQ: PEIX), the leading marketer and producer of low-carbon renewable fuels in the Western United States.

BG Medicine, Inc. Announces Important New Galectin-3 Findings Presented at American College of Cardiology's (ACC) 61st Annual Scientific Session & Expo

BG Medicine, Inc. Announces Important New Galectin-3 Findings Presented at American College of Cardiology's (ACC) 61st Annual Scientific Session & Expo

March 26, 2012

BG Medicine, Inc. (Nasdaq:BGMD - News), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today the results of several new studies related to the galectin-3 protein. BG Medicine markets a blood test for galectin-3 called the BGM Galectin-3 test for heart failure, which was cleared by the FDA in 2010 and obtained the CE mark for commercialization in the EU.

LS9

LS9 Wins Sustainable Biofuels Technology Award Presented by World Biofuels Markets

LS9 Wins Sustainable Biofuels Technology Award Presented by World Biofuels Markets

March 16, 2012

 SOUTH SAN FRANCISCO, Calif., Mar 16, 2012 (GlobeNewswire via COMTEX) -- LS9, Inc., a technology leader in the development of renewable and sustainable products, today announced the Company was chosen by an independent panel of judges as the winner of the Sustainable Biofuels Technology Award presented at the World Biofuels Markets Congress and Exhibition 2012 taking place March 13-15, 2012 at the Beurs-World Trade Center, in the Rotterdam, Netherlands ( www.worldbiofuelsmarkets.com ).<

LS9

LS9 Wins Sustainable Biofuels Technology Award Presented by World Biofuels Markets

LS9 Wins Sustainable Biofuels Technology Award Presented by World Biofuels Markets

February 16, 2012

 SOUTH SAN FRANCISCO, Calif., Mar 16, 2012 (GlobeNewswire via COMTEX) -- LS9, Inc., a technology leader in the development of renewable and sustainable products, today announced the Company was chosen by an independent panel of judges as the winner of the Sustainable Biofuels Technology Award presented at the World Biofuels Markets Congress and Exhibition 2012 taking place March 13-15, 2012 at the Beurs-World Trade Center, in the Rotterdam, Netherlands ( www.worldbiofuelsmarkets.com ).<

Black Duck Software, Inc.

Tom Bogan Joins Black Duck Software as Chairman of the Board

Tom Bogan Joins Black Duck Software as Chairman of the Board

March 15, 2012

BURLINGTON, Mass., March 15, 2012 -- Black Duck Software, the leader in open source software knowledge,

Celexion LLC

CELEXION Awarded Patent on Biosynthesis of Renewable Chemicals

CELEXION Awarded Patent on Biosynthesis of Renewable Chemicals

March 14, 2012

CAMBRIDGE, Mass., March 14, 2012